国内版 国际版

Neural stem cell transplantation therapy for brain ischemic stroke: review and pers

All Images Videos 翻译成中文 关闭取词

27,800 Results Any time

Stem Cell Therapy in Stroke: A Review Literature

https://**www.ncbi.nlm.nih.gov**/pmc/articles/PMC3678210

Feb 21, 2013 · Embryonic **stem cells** and iPSs **cells**. In 1998, ESCs were first originated from the inner **cell** mass of blastocysts.[] These **cells** can be differentiated by various methods into **neural** progenitor **cells**.[] In animal model, ESCs **cells** derived **neural cells** could survive in **stroke** lesions of **brain**, and differentiated into mature neurons.[] However, there are potential concerns following ESC application.

Cited by: 8 **Author:** Rokhsareh Meamar, Leila Dehghani, Maji...
Publish Year: 2013

Neural stem cell therapy for subacute and chronic ischemic ...

https://**stemcell**res.biomedcentral.com/articles/10.1186/s13287-018-0913-2

Jun 13, 2018 · **Neural stem cells** (NSCs) play vital roles in **brain** homeostasis and exhibit a broad repertoire of potentially therapeutic actions following neurovascular injury. One such injury is **stroke**, a worldwide leading cause of death and disability. Clinically, extensive injury from **ischemic stroke** results from ischemia-reperfusion (IR), which is accompanied by inflammation, blood-**brain** barrier (BBB ...

Cited by: 9 **Author:** Austin C. Boese, Quan-Son Eric Le, Dyla...
Publish Year: 2018

Current state and perspectives of stem cell therapy for stroke

https://www.sciencedirect.com/science/article/pii/S1665579616300710

Stem cell therapy for **stroke** Design of clinical trial. The first attempt to treat **stroke** using **stem cells** was more than 15 years ago. 91 Hitherto there is still no optimum model for a clinical trial. With **stroke** being so diverse and many aspects of **stem cell therapy** still unexplored, many variables have to be thrown into the equation.

Author: D.M. Martínez-Garza, O.G. Cantú-Ro... **Publish Year:** 2016

Human stem cell therapy in ischaemic stroke: a review ...

https://academic.oup.com/ageing/article/40/1/7/11574

Nov 10, 2010 · Approaches to **stem cell therapy** in ischaemic **stroke**. Human **stem cell transplantation therapy** is a now a well-established **treatment** for various malignant and non-malignant haematological diseases and some autoimmune disorders. Pre-clinical studies over the last decade have demonstrated significant benefits of **stem cell therapy** in rodent models ...

Cited by: 59 **Author:** Soma Banerjee, Deborah Williamson, Na...
Publish Year: 2011 **Author:** Banerjee, Soma

Neural stem cell transplantation therapy for brain ischemic stroke: Review and perspectives

Gui-Long Zhang, Zhi-Han Zhu, Ye-Zhong Wang

Abstract

Brain ischemic stroke is one of the most common causes of death and disability, currently has no efficient therapeutic strategy in clinic. Due to irreversible functional neurons loss and neural tissue injury, stem cell transplantation may be the most promising treatment approach. Neural stem cells (NSCs) as the special type of stem cells only exist in the nervous system, can differentiate into neurons, astrocytes, and oligodendrocytes, and have the abilities to compensate insufficient endogenous nerve cells and improve the inflammatory microenvironment of cell survival. In this review, we focused on the important role of NSCs therapy for brain ischemic stroke, mainly introduced the methods of optimizing the therapeutic efficacy of NSC transplantation, such as transfection and overexpression of specific genes, pretreatment of NSCs with inflammatory factors, and co-transplantation with cytokines. Next, we discussed the potential problems of NSC transplantation which seriously limited their rapid clinical transformation and application. Finally, we expected

国内版 国际版

Neural stem cell transplantation therapy for brain ischemic stroke: Review and per:

All Images Videos 翻译成中文 关闭取词

25,900 Results Any time

Stem Cell Therapy in Stroke: A Review Literature

https://**www.ncbi.nlm.nih.gov**/pmc/articles/PMC3678210

Feb 21, 2013 · Embryonic **stem cells** and iPSs **cells**. In 1998, ESCs were first originated from the inner **cell** mass of blastocysts.[] These **cells** can be differentiated by various methods into **neural** progenitor **cells**.[] In animal model, ESCs **cells** derived **neural cells** could survive in **stroke** lesions of **brain**, and differentiated into mature neurons.[] However, there are potential concerns following ESC application.

Cited by: 8 **Author:** Rokhsareh Meamar, Leila Dehghani, Maji...
Publish Year: 2013

Neural stem cell therapy for subacute and chronic ischemic ...

https://**stemcell**res.biomedcentral.com/articles/10.1186/s13287-018-0913-2

Jun 13, 2018 · **Neural stem cells** (NSCs) play vital roles in **brain** homeostasis and exhibit a broad repertoire of potentially therapeutic actions following neurovascular injury. One such injury is **stroke**, a worldwide leading cause of death and disability. Clinically, extensive injury from **ischemic stroke** results from ischemia-reperfusion (IR), which is accompanied by inflammation, blood-**brain** barrier (BBB ...

Cited by: 12 **Author:** Austin C. Boese, Quan-Son Eric Le, Dyla...
Publish Year: 2018 **Author:** Austin C. Boese

Current state and perspectives of stem cell therapy for stroke

https://www.sciencedirect.com/science/article/pii/S1665579616300710

Stem cell therapy for **stroke** Design of clinical trial. The first attempt to treat **stroke** using **stem cells** was more than 15 years ago. 91 Hitherto there is still no optimum model for a clinical trial. With **stroke** being so diverse and many aspects of **stem cell therapy** still unexplored, many variables have to be thrown into the equation.

Cited by: 1 **Author:** D.M. Martínez-Garza, O.G. Cantú-Rodríg...
Publish Year: 2016

Human stem cell therapy in ischaemic stroke: a review ...

https://academic.oup.com/ageing/article/40/1/7/11574

Nov 10, 2010 · Approaches to **stem cell therapy** in ischaemic **stroke**. Human **stem cell transplantation therapy** is a now a well-established **treatment** for various malignant and non-malignant haematological diseases and some autoimmune disorders. Pre-clinical studies over the last decade have